8th June 2025, During the 66th meeting of the Drugs Consultative Committee (DCC) held at CDSCO, New Delhi, a significant regulatory concern regarding the unauthorized issuance of manufacturing licenses for new drugs by certain State Licensing Authorities (SLAs) was deliberated. ⚠️…
Apart from regulatory requirements, labelling of pharmaceutical products is required for identifying the content of drug, for providing administration instruction, storage requirement, expiry of the drug product etc. Labels should be able to provide essential and comprehensive information to patients…
Recent Post
- India brings Pregabalin under Schedule H1
- CDSCO Issues Stern Warning Against Injectable Cosmetics and Misleading Beauty Claims
- CDSCO Orders Nationwide Crackdown on Unauthorised GLP-1 Weight Loss Drugs
- Drug Applications with Unanswered Queries to Be Rejected Within 30 Days by CDSCO
- ⚖️ “No Approval, No Market”: Delhi High Court Sends a Strong Message on Unapproved Drugs & FDCs
